Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **glycine receptor alpha 4** (GLRA4) gene is a member of the Cys-loop ligand-gated ion channel receptor family. In humans, GLRA4 is classified as a pseudogene, as the encoded protein carries multiple inactivating mutations and lacks a functional fourth transmembrane region, meaning it does not produce an active glycine receptor subunit. Therefore, GLRA4 does not form functional receptors or participate in inhibitory neurotransmission in human physiology[1][2][3][4][5]. In other vertebrates (such as rodents and zebrafish), the glycine receptor alpha 4 subunit is expressed and contributes to synaptic inhibition, particularly in mediating startle and escape responses[1]. Summary of issues: GLRA4 is frequently mischaracterized as a standard glycine receptor subunit target in humans, but all evidence from molecular, genetic, and electrophysiological studies demonstrate that the human gene is nonfunctional (pseudogene)[1][2][3][4][5]. For target-based drug design or biomarker purposes, GLRA4 should not be considered, unless referring to non-human species.
not a drug target; see above
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glycine receptor alpha 4 (GLRA4).